Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide
- PMID: 2140341
- PMCID: PMC258732
- DOI: 10.1128/iai.58.6.1835-1842.1990
Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide
Abstract
Previous studies have shown that antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) can be divided into two types on the basis of their functional activity. One type is able to mediate opsonic killing in conjunction with leukocytes and complement, and the other type is not. We investigated, in mice, the properties of this antigen associated with elicitation of opsonic killing antibody. We found that smaller-sized material (Kav = 0.26), which has been tested as a human vaccine, elicited opsonic killing antibody in mice at low doses (1 to 10 micrograms) and at doses of greater than or equal to 40 micrograms, only nonopsonic killing antibody was produced. A similar dose effect was seen with heat-killed mucoid P. aeruginosa cells. After immunization with high doses of this MEP or the heat-killed cells, the mice were refractory to induction of opsonic killing antibody no matter what dose of MEP was used as a booster. In contrast, a larger-molecular-weight preparation (Kav = 0.05) elicited opsonic killing antibody over a wide dose range (1 to 400 micrograms). Additionally, 50 micrograms of the larger-sized preparation could overcome the suppression induced by 50 micrograms of the smaller material. Suppression elicited by 50 micrograms of the smaller material could be adoptively transferred to nonimmune mice with the T-cell fraction of spleen cells. These results indicate that both molecular size and dose are critical determinants for eliciting opsonic killing antibody to mucoid P. aeruginosa after immunizing with MEP.
Similar articles
-
Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.Infect Immun. 1994 Sep;62(9):3972-9. doi: 10.1128/iai.62.9.3972-3979.1994. Infect Immun. 1994. PMID: 8063415 Free PMC article.
-
Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.Infect Immun. 2003 Jul;71(7):3875-84. doi: 10.1128/IAI.71.7.3875-3884.2003. Infect Immun. 2003. PMID: 12819072 Free PMC article.
-
Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins.J Immunol. 1991 Sep 15;147(6):1869-76. J Immunol. 1991. PMID: 1832427
-
Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.Behring Inst Mitt. 1997 Feb;(98):350-60. Behring Inst Mitt. 1997. PMID: 9382760 Review.
-
Pseudomonas aeruginosa antigens as potential vaccines.FEMS Microbiol Rev. 1997 Nov;21(3):243-77. doi: 10.1111/j.1574-6976.1997.tb00353.x. FEMS Microbiol Rev. 1997. PMID: 9451816 Review.
Cited by
-
Suppression of lymphocyte and neutrophil functions by Pseudomonas aeruginosa mucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments.Infect Immun. 1993 Feb;61(2):559-64. doi: 10.1128/iai.61.2.559-564.1993. Infect Immun. 1993. PMID: 8423085 Free PMC article.
-
Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.J Clin Invest. 1993 Mar;91(3):1079-87. doi: 10.1172/JCI116265. J Clin Invest. 1993. PMID: 8450038 Free PMC article.
-
Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.Infect Immun. 1994 Sep;62(9):3972-9. doi: 10.1128/iai.62.9.3972-3979.1994. Infect Immun. 1994. PMID: 8063415 Free PMC article.
-
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.Microbiol Rev. 1996 Sep;60(3):539-74. doi: 10.1128/mr.60.3.539-574.1996. Microbiol Rev. 1996. PMID: 8840786 Free PMC article. Review.
-
Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.Infect Immun. 1994 Aug;62(8):3146-55. doi: 10.1128/iai.62.8.3146-3155.1994. Infect Immun. 1994. PMID: 8039883 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources